TY - JOUR
T1 - A meta-analytic review of psychosocial interventions for substance use disorders
AU - Dutra, Lissa
AU - Stathopoulou, Georgia
AU - Basden, Shawnee L.
AU - Leyro, Teresa M.
AU - Powers, Mark B.
AU - Otto, Michael W.
PY - 2008/2
Y1 - 2008/2
N2 - Objective: Despite significant advances in psychosocial treatments for substance use disorders, the relative success of these approaches has not been well documented. In this meta-analysis, the authors provide effect sizes for various types of psychosocial treatments, as well as abstinence and treatment-retention rates for cannabis, cocaine, opiate, and polysubstance abuse and dependence treatment trials. Method: With a comprehensive series of literature searches, the authors identified a total of 34 well-controlled treatment conditions - five for cannabis, nine for cocaine, seven for opiate, and 13 for polysubstance users - representing the treatment of 2,340 patients. Psychosocial treatments evaluated included contingency management, relapse prevention, general cognitive behavior therapy, and treatments combining cognitive behavior therapy and contingency management. Results: Overall, controlled trial data suggest that psychosocial treatments provide benefits reflecting a moderate effect size according to Cohen's standards. These interventions were most efficacious for cannabis use and least efficacious for polysubstance use. The strongest effect was found for contingency management interventions. Approximately one-third of participants across all psychosocial treatments dropped out before treatment completion compared to 44.6% for the control conditions. Conclusions: Effect sizes for psychosocial treatments for illicit drugs ranged from the low-moderate to high-moderate range, depending on the substance disorder and treatment under study. Given the long-term social, emotional, and cognitive impairments associated with substance use disorders, these effect sizes are noteworthy and comparable to those for other efficacious treatments in psychiatry.
AB - Objective: Despite significant advances in psychosocial treatments for substance use disorders, the relative success of these approaches has not been well documented. In this meta-analysis, the authors provide effect sizes for various types of psychosocial treatments, as well as abstinence and treatment-retention rates for cannabis, cocaine, opiate, and polysubstance abuse and dependence treatment trials. Method: With a comprehensive series of literature searches, the authors identified a total of 34 well-controlled treatment conditions - five for cannabis, nine for cocaine, seven for opiate, and 13 for polysubstance users - representing the treatment of 2,340 patients. Psychosocial treatments evaluated included contingency management, relapse prevention, general cognitive behavior therapy, and treatments combining cognitive behavior therapy and contingency management. Results: Overall, controlled trial data suggest that psychosocial treatments provide benefits reflecting a moderate effect size according to Cohen's standards. These interventions were most efficacious for cannabis use and least efficacious for polysubstance use. The strongest effect was found for contingency management interventions. Approximately one-third of participants across all psychosocial treatments dropped out before treatment completion compared to 44.6% for the control conditions. Conclusions: Effect sizes for psychosocial treatments for illicit drugs ranged from the low-moderate to high-moderate range, depending on the substance disorder and treatment under study. Given the long-term social, emotional, and cognitive impairments associated with substance use disorders, these effect sizes are noteworthy and comparable to those for other efficacious treatments in psychiatry.
UR - http://www.scopus.com/inward/record.url?scp=40949093457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40949093457&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2007.06111851
DO - 10.1176/appi.ajp.2007.06111851
M3 - Article
C2 - 18198270
AN - SCOPUS:40949093457
SN - 0002-953X
VL - 165
SP - 179
EP - 187
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 2
ER -